Journal of Antimicrobial Chemotherapy, Vol 40, 27-32, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
YI Ho, CY Chan and AF Cheng
Aminoglycoside-aminocyclitols including streptomycin, kanamycin,
capreomycin and amikacin showed considerable activity against Mycobacterium
tuberculosis, with MICs well below their Cmax and relatively low MBC/MIC
ratios. Kanamycin, capreomycin and amikacin remained highly active against
'resistant' and 'multidrug-resistant' M. tuberculosis isolates except for
some 'multidrug-resistant' isolates which showed complete cross-resistance
between streptomycin and the selected 2-deoxystreptamines. Gentamicin
displayed anti-tuberculous activity but was bacteriostatic only.
Non-tuberculosis mycobacteria, in particular Mycobacterium chelonae and
Mycobacterium avium- intracellulare, were more resistant than M.
tuberculosis. Amikacin was inhibitory against Mycobacterium kanasii,
Mycobacterium scrofulaceum and Mycobacterium fortuitum, but was
bactericidal against M. scrofulaceum only. Kanamycin was also bactericidal
against M. scrofulaceum. Growth of M. fortuitum was inhibited by amikacin
and neomycin which was also inhibitory against M. tuberculosis and M.
scrofulaceum. Although the application of neomycin has been limited by its
high toxicity, this study suggested that this drug might be useful as a
topical agent for cutaneous infections by M. fortuitum.
ORIGINAL ARTICLES
In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria
Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin NT.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. H. Wright, G. H. Brown, M. L. Peterson, and J. C. Rotschafer Application of fluoroquinolone pharmacodynamics J. Antimicrob. Chemother., November 1, 2000; 46(5): 669 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. I. Y. Ho, C. Y. Chan, and A. F. B. Cheng Aminoglycoside Resistance in Mycobacterium kansasii, Mycobacterium avium-M. intracellulare, and Mycobacterium fortuitum: Are Aminoglycoside-Modifying Enzymes Responsible? Antimicrob. Agents Chemother., January 1, 2000; 44(1): 39 - 42. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Legg and A. J. Bint Will pneumococci put quinolones in their place? J. Antimicrob. Chemother., October 1, 1999; 44(4): 425 - 427. [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Chen, A. McGeer, J. C. de Azavedo, D. E. Low, and The Canadian Bacterial Surveillance Network Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada N. Engl. J. Med., July 22, 1999; 341(4): 233 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. MacGowan, K. E. Bowker, M. Wootton, and H. A. Holt Activity of Moxifloxacin, Administered Once a Day, against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model of Infection Antimicrob. Agents Chemother., July 1, 1999; 43(7): 1560 - 1564. [Abstract] [Full Text]
|
|
|
|
|
|
M. Dedicoat and P. Venkatesan The treatment of Legionnaires' disease J. Antimicrob. Chemother., June 1, 1999; 43(6): 747 - 752. [Full Text] [PDF]
|
|